Insider Transactions in Q4 2021 at Viracta Therapeutics, Inc. (VIRX)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2021
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+1.2%
|
$0
$0.9 P/Share
|
|
Nov 29
2021
|
Ivor Royston |
SELL
Open market or private sale
|
Direct |
15,833
-2.7%
|
$63,332
$4.82 P/Share
|
|
Nov 29
2021
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
4,325
-5.6%
|
$17,300
$4.82 P/Share
|
|
Nov 29
2021
|
Lisa Rojkjaer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,591
-6.31%
|
$10,364
$4.82 P/Share
|
|
Nov 26
2021
|
Ivor Royston |
SELL
Open market or private sale
|
Direct |
11,914
-1.99%
|
$47,656
$4.8 P/Share
|
|
Nov 26
2021
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
3,254
-4.04%
|
$13,016
$4.8 P/Share
|
|
Nov 26
2021
|
Lisa Rojkjaer Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,950
-4.53%
|
$7,800
$4.8 P/Share
|
|
Nov 25
2021
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
50,437
+7.77%
|
-
|
|
Nov 25
2021
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,777
+14.61%
|
-
|
|
Nov 25
2021
|
Lisa Rojkjaer Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,254
+16.1%
|
-
|
|
Nov 25
2021
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
18,068
+50.0%
|
-
|
|
Nov 15
2021
|
Ivor Royston |
BUY
Open market or private purchase
|
Direct |
8,000
+1.44%
|
$40,000
$5.56 P/Share
|